2024-11-07 - Analysis Report
## Pfizer Inc (PFE) Stock Analysis Report

**1. Stock Performance:**

Pfizer Inc (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines. Its share price has declined significantly, **losing 15.35%** in the period under review, while the S&P 500 (VOO) has gained **139.88%**. This represents a **-155.23%** performance difference, putting PFE **at the bottom 0%** of its historical performance against the S&P 500.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | 15.6% | 17.9% | -14.6% | 0.8 |
| 2016-2018 | 36.6% | 17.9% | 11.9% | 0.7 |
| 2017-2019 | 18.7% | 22.5% | -24.4% | 0.8 |
| 2018-2020 | 6.5% | 32.9% | -32.6% | 0.7 |
| 2019-2021 | 43.9% | 32.9% | -45.9% | 0.6 |
| 2020-2022 | 38.0% | 29.5% | 20.2% | 0.6 |
| 2021-2023 | -21.8% | 49.7% | -50.6% | 0.4 |
| 2022-2024 | -51.7% | 46.1% | -75.4% | 0.5 |

PFE's **beta** has been consistently below 1, indicating **lower volatility than the market**. However, the **alpha** has been negative in most of the past years, showing PFE **underperforming compared to the market**.

**2. Recent Price Movement:**

* Closing price: $27.36
* 5-day moving average: $27.9
* 20-day moving average: $28.71
* 60-day moving average: $28.93

The stock price is currently below all moving averages, indicating **short-term downward pressure**.

**3. Technical Indicators:**

* **RSI:** 21.49 - This indicates that PFE is **oversold** and could potentially bounce back.
* **PPO:** -0.49 - This suggests **weak momentum** and potential for further decline.
* **Delta_Previous_Relative_Divergence:** -1.22 - This shows **short-term downward momentum**.
* **Expected Return:** 0.0 - This indicates that the stock is expected to **perform in line with the market** over the long term.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

The latest earnings report (2024-10-29) showed a **positive surprise**, with EPS exceeding expectations. However, previous quarters have shown mixed results.  Analysts expect a **positive outlook** for PFE going forward.

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $17.70B | 70.27% |
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.49B | 31.30% |

PFE's revenue has remained steady, with **high profitability margins**.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $92.29B | 4.84% |
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |

PFE has a **strong capital position** with fluctuating ROE,  potentially due to the impact of specific events or business decisions.

**6. News and Recent Issues:**

* **Recent Earnings News:**  Pfizer reported **better-than-expected earnings** for the third quarter of 2024, exceeding analyst forecasts. This news was positively received by the market.
* **Recent Market Outlook:**  Analysts remain optimistic about PFE's long-term growth prospects, driven by its strong pipeline of new drugs and vaccines. However, the current market sentiment is influenced by concerns over generic competition and potential pricing pressure.
* **Analyst Opinions:** Most analysts have a **buy or outperform rating** for PFE, with the average price target exceeding the current stock price.  
* **Performance Highlights:** PFE has historically demonstrated strong performance during market downturns due to its defensive nature as a pharmaceutical company.

**7. Summary:**

PFE is a pharmaceutical giant with a strong financial position and a promising pipeline of new drugs. However, its share price has been underperforming the market in the recent period.  While recent earnings have been positive, investors should be aware of the potential headwinds, such as generic competition and pricing pressure.  PFE's  strong fundamentals and long-term growth prospects make it a potential buy for investors with a long-term investment horizon.

**Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice. 
